Visual disturbances due to semaglutide: A systematic review of the literature
DOI:
https://doi.org/10.62486/ijn2025247Keywords:
Semaglutide, Vision, Type 2 Diabetes, Ophthalmological Risks, EffectsAbstract
Introduction: Semaglutide is a widely used medication for the management of type 2 diabetes and, more recently, for the treatment of obesity. While it is known for its efficacy in controlling glycemia and promoting weight loss, side effects have also been reported, including some related to vision. These side effects are uncommon but may be indirectly linked. Objectives: This study aimed to analyze the available evidence on visual disturbances associated with the use of semaglutide, describing the possible pathophysiological mechanisms involved and its clinical impact on patients. Materials and methods: A systematic review of the literature was conducted in scientific databases such as PubMed, Medscape, Scopus, and Cochrane, evaluating the incidence, severity, and reversibility of these adverse effects. Results: Several studies that demonstrated the ophthalmological risk associated with the use of semaglutide were selected. Conclusion: Although semaglutide has several proven benefits as a medication for type 2 diabetes, its use poses some risks that should be actively investigated, primarily the ophthalmological risks associated with semaglutide, especially in patients with a history of eye disease.
References
1. Fourtune Journals (2025). Semaglutida: un arma de doble filo con riesgos y beneficios. Recuperado en 05 de julio de 2025, de https://www.fortunejournals.com/ articles/semaglutide-doubleedged-sword-with-risks-and-benefits.html
2. Medicina y Salud Publica (2024). Identifican posible vínculo entre semaglutida y pérdida de visión en pacientes con diabetes y obesidad. Recuperado en 05 de julio de 2025, de https://medicinaysaludpublica.com/ noticias/investigacion/identifican-posible-vinculo-entre-semaglutida-y-perdida-de-vision-en-pacientes-con-diabetes-y-obesidad/24190
3. Pubmed (2025). Neuropatía óptica isquémica anterior en pacientes tratados con semaglutida: reporte de cuatro casos con posible asociación. Recuperado en 15 de abril de 2025, de https://pubmed.ncbi. nlm.nih.gov/40087651/
4. Consejo Brasileño de Oftalmologia. (s.f.). Ozempic e saúde ocular. Recuperado el 18 de febrero de 2025, de https://coioftalmologia.com.br/blog/geral/ozempic-e-saude-ocular/
5. Revista Española de Cardiología. (2022). Abordaje práctico de semaglutida en el paciente cardiovascular de alto riesgo. Revista Española de Cardiología. Recuperado en 18 de Febrero de 2025, de https://www.revespcardiol.org/es-abordaje-practico-semaglutida-el-paciente-articulo-S1131358722000139
6. Pubmed. (2022)Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Recuperado en 18 de febrero de 2025, de https://pubmed.ncbi.nlm.nih.gov/34894326/
7. Elsevier (2022). Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis. Recuperado el 18 de febrero de 2025, de https://www.sciencedirect.com/science/ article/abs/pii/S1056872722001647?via%3Dihub
8. Medscape. (s.f.). Identifican posible vínculo entre semaglutida y pérdida de visión en pacientes con diabetes y obesidad. Recuperado el 18 de enero de 2025, de https://espanol.medscape.com/verarticulo/5910345?scode=msp&st=fpf&socialSite=google&form=fpf
9. PubMed. (2021). Effects of semaglutide on weight loss and metabolic parameters: A systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism. Recuperado el 20 de enero de 2025, de https://pubmed.ncbi. nlm.nih.gov/34281590
10. Medicina y Salud Pública. (2024). Identifican posible vínculo entre semaglutida y pérdida de visión en pacientes con diabetes y obesidad. Recuperado el 18 de febrero de 2025, de https://medicinaysaludpublica.com/ noticias/investigacion/identifican-posible-vinculo-entre-semaglutida-y-perdida-de-vision-en-pacientes-con-diabetes-y-obesidad/24190
11. Pubmed. (2022). Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Recuperado el 18 de febrero de 2025, de https://pubmed.ncbi.nlm.nih.gov/3793853 5/
12. MedlinePlus. (s.f.). Semaglutida. Biblioteca Nacional de Medicina de EE. UU. Recuperado el 18 de febrero de 2025, de https://medlineplus.gov/spanish/druginfo/meds/a618008-es.html
13. Medscape. (2023). El examen oftalmológico es importante antes de empezar el tratamiento con semaglutida en diabetes. Recuperado en 18 de febrero de 2025, de https://espanol.medscape.com/ver articulo/5910345?scode=msp&st=fpf&socialSite=google&form=fpf
14. Pubmed. (2024). Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies. Recuperado el 18 de febrero de 2025, de https://pubmed.ncbi.nlm.nih.gov/3803123 4/
15. Medscape (2024). Semaglutida vinculada a la pérdida de visión. Recuperado en 05 de julio de 2025, de https://www.medscape.com/viewarticle/semaglutide-linked-cause-vision-loss-2024a1000cd7.
Published
Issue
Section
License
Copyright (c) 2025 Camila Barreto Maciel, Marcelo Adrian Estrin (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
